

Yukinori Nagakura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8743628/publications.pdf>

Version: 2024-02-01

42
papers

1,087
citations

471509

17
h-index

395702

33
g-index

44
all docs

44
docs citations

44
times ranked

1362
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Approaches to Nociceptive Pain Based on Findings in the Reserpine-Induced Fibromyalgia-Like Animal Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, , JPET-MR-2021-001051.	2.5	0
2	Lifestyle habits to prevent the development of benign prostatic hyperplasia: Analysis of Japanese nationwide datasets. <i>Prostate International</i> , 2022, 10, 200-206.	2.3	4
3	Potential Molecular Targets for Treating Neuropathic Orofacial Pain Based on Current Findings in Animal Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6406.	4.1	10
4	The Significant Association between Health Examination Results and Population Health: A Cross-Sectional Ecological Study Using a Nation-Wide Health Checkup Database in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 836.	2.6	6
5	Country and Gender Differences in the Color Association with Energy Drinks: A Survey in Taiwanese and Japanese Students. <i>Foods</i> , 2020, 9, 1670.	4.3	0
6	The method simulating spontaneous pain in patients with nociceptive pain using rats with fibromyalgia-like condition. <i>MethodsX</i> , 2020, 7, 100826.	1.6	7
7	Spontaneous pain-associated facial expression and efficacy of clinically used drugs in the reserpine-induced rat model of fibromyalgia. <i>European Journal of Pharmacology</i> , 2019, 864, 172716.	3.5	21
8	Coexistence of Alterations of Gastrointestinal Function and Mechanical Allodynia in the Reserpine-Induced Animal Model of Fibromyalgia. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2538-2547.	2.3	7
9	Monoamine system disruption induces functional somatic syndromes associated symptomatology in mice. <i>Physiology and Behavior</i> , 2018, 194, 505-514.	2.1	14
10	Giving priority to preclinical pain measures resistant to existing drugs for developing innovative analgesics. <i>Drug Development Research</i> , 2018, 79, 147-156.	2.9	1
11	The need for fundamental reforms in the pain research field to develop innovative drugs. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 39-46.	5.0	18
12	Spontaneous and evoked pain-associated behaviors in a rat model of neuropathic pain respond differently to drugs with different mechanisms of action. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 141, 10-17.	2.9	33
13	Recent Advancements in Animal Models of Fibromyalgia. <i>Myopain</i> , 2015, 23, 104-111.	0.0	12
14	Challenges in drug discovery for overcoming “dysfunctional pain”: an emerging category of chronic pain. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1043-1045.	5.0	33
15	Efficacy of drugs with different mechanisms of action in relieving spontaneous pain at rest and during movement in a rat model of osteoarthritis. <i>European Journal of Pharmacology</i> , 2014, 738, 111-117.	3.5	45
16	Systemic administration of 5-HT _{2C} receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 108, 8-15.	2.9	26
17	Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: Comparison of reserpine-induced myalgia and chronic constriction injury rats. <i>Behavioural Brain Research</i> , 2012, 226, 242-249.	2.2	38
18	Response to the “Letter to the Editor of Pain” by Dr. Munro. <i>Pain</i> , 2010, 148, 173-174.	4.2	0

#	ARTICLE	IF	CITATIONS
19	Assessment of canine sensory function by using sine-wave electrical stimuli paradigm. Physiology and Behavior, 2010, 101, 327-330.	2.1	5
20	Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain, 2009, 146, 26-33.	4.2	173
21	Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X2/3 receptor function and exerts an analgesic effect in pain models. European Journal of Pharmacology, 2008, 589, 98-101.	3.5	35
22	Determination of current threshold for paw withdrawal with sine-wave electrical stimulation in rats: Effect of drugs and alteration in acute inflammation. Pain, 2008, 134, 293-301.	4.2	13
23	The sensitization of a broad spectrum of sensory nerve fibers in a rat model of acute postoperative pain and its response to intrathecal pharmacotherapy. Pain, 2008, 139, 569-577.	4.2	13
24	Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. European Journal of Pharmacology, 2007, 571, 8-16.	3.5	23
25	Radioligand Binding Properties and Pharmacological Characterization of 6-Amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a High-Affinity, Selective, and Noncompetitive Antagonist of Metabotropic Glutamate Receptor Type 1. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 163-169.	2.5	90
26	Allodynia and Hyperalgesia in Adjuvant-Induced Arthritic Rats: Time Course of Progression and Efficacy of Analgesics. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 490-497.	2.5	152
27	The effect of the selective 5-HT3 receptor agonist on ferret gut motility. Life Sciences, 2002, 71, 1313-1319.	4.3	15
28	Stimulation of gastric acid secretion by progesterone metabolites as neuroactive steroids in anesthetized rats. Journal of Physiology (Paris), 2000, 94, 111-116.	2.1	11
29	Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. European Journal of Pharmacology, 2000, 409, 195-201.	3.5	18
30	The role of 5-hydroxytryptamine3 and 5-hydroxytryptamine 4 receptors in the regulation of gut motility in the ferret. Life Sciences, 2000, 66, PL331-PL338.	4.3	4
31	PHARMACOLOGICAL PROPERTIES OF A NOVEL GASTROINTESTINAL PROKINETIC BENZAMIDE SELECTIVE FOR HUMAN 5-HT4RECEPTORVERSUSHUMAN 5-HT3RECEPTOR. Pharmacological Research, 1999, 39, 375-382.	7.1	24
32	Synthesis of the Selective 5-Hydroxytryptamine 4 (5-HT4) Receptor Agonist (+)-(S)-2-Chloro-5-methoxy-4-(5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-yl)aniline.. Chemical and Pharmaceutical Bulletin, 1999, 47, 120-122.	1.3	8
33	The Selective 5-Hydroxytryptamine (5-HT)4-Receptor Agonist RS67506 Enhances Lower Intestinal Propulsion in Mice.. The Japanese Journal of Pharmacology, 1997, 74, 209-212.	1.2	19
34	Gastrointestinal motor activity in conscious ferrets. European Journal of Pharmacology, 1997, 321, 53-57.	3.5	6
35	Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs. European Journal of Pharmacology, 1997, 327, 189-193.	3.5	11
36	The Selective 5-Hydroxytryptamine (5-HT)4-Receptor Agonist RS67506 Enhances Lower Intestinal Propulsion in Mice. The Japanese Journal of Pharmacology, 1997, 74, 209-212.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Effects of gastroprokinetic agents on gastroparesis in streptozotocin-induced diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 145-150.	3.0	28
38	Compounds possessing 5-HT ₃ receptor antagonistic activity inhibit intestinal propulsion in mice. European Journal of Pharmacology, 1996, 311, 67-72.	3.5	78
39	Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 353, 489-98.	3.0	31
40	Mechanisms of cisplatin- and m-chlorophenylbiguinide-induced emesis in ferrets. European Journal of Pharmacology, 1993, 238, 369-376.	3.5	50
41	Effects of perfusion flow rate, prostaglandin F ₂ ±, phenylephrine, and serotonin on isolated, perfused brains of spontaneously hypertensive rats. Brain Research, 1989, 482, 122-128.	2.2	0
42	Animal Models of Fibromyalgia. , 0, , .		2